ARISE
Financiado
African Research and Innovative Initiative for Sickle cell Education Improving...
African Research and Innovative Initiative for Sickle cell Education Improving Research Capacity for Service Improvement
The Overarching Objective for this consortium is to establish an inter-agency and multidisciplinary staff exchange programme between researchers, technical and administrative staff interaction within EU institutions as well as rea...
The Overarching Objective for this consortium is to establish an inter-agency and multidisciplinary staff exchange programme between researchers, technical and administrative staff interaction within EU institutions as well as reaching out to non-EU countries in Africa, Lebanon and US in order to foster sharing of best practice in Newborn Screening, diagnosis and treatment of Sickle Cell Disease (SCD) leading to improvement in overall disease outcome. Using implementation science strategies for this consortium to foster partnerships and the establishment of patient database, registries and a sustainable service for people living with the disorder.
Primary Objectives:
- To evaluate the prevalence of sickle cell disease among populations in consortium member countries and identify specific haemoglobin genotypes and phenotypic presentations;
- To establish laboratory diagnosis and quality assurance systems for population screening and setting up of SCD national prevention programmes;
- To test the feasibility for establishing newborn and early infant screening for SCD in consortium participants;
- To establish treatment protocols for common complications -acute and chronic pain, stroke, infections, severe anaemia as well as transition from paediatric to adult care, health promotion strategies and nutrition.
In order to achieve these objectives, we designed the following WPs:
Scientific Coordination and Project Management
Implementing eHealth technologies to support a Newborn screening programme in EU, African Countries and Lebanon.
Improving laboratory diagnosis and quality assurance systems for population screening.
Newborn SCD screening, screening for neurocognitive complications, clinical care and antibiotic prophylaxis
Enhancement of SCD management through training in molecular diagnostic techniques and Genetic Counseling for haemoglobinopathies and performance of epidemiological and
Training in Research and academic leadership.
Communication and dissemination
ver más
Duración del proyecto: 72 meses
Fecha Inicio: 2018-10-26
Fecha Fin: 2024-10-31
Fecha Fin: 2024-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2024-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-RISE-2018:
Research and Innovation Staff Exchange
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANN...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
282.79K€ |
Participante